Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recifercept · 1 trial · 1 indication
AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
Area under the concentration curve from time 0 to end of dosing interval (AUCtau)
Maximum Observed Plasma Concentration directly from data
Time to reach Cmax
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Accumulation ratio was calculated as, Rac obtained from Area Under the Concentration Time Curve (AUC) from time 0-t (Day X) divided by AUC from time 0-t (Day 1).
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | Repeated multiple doses |
| placebo | PLACEBO_COMPARATOR | Repeated multiple doses |
| High Dose | EXPERIMENTAL | Repeated multiple doses |
| Name | Type | Description |
|---|---|---|
| Recifercept | DRUG | recifercept powder for solution for injection |
| Placebo | OTHER | solution for injection |
Inclusion Criteria: * Male participants and female participants of nonchildbearing potential * Participants who are overtly healthy * Capable of giving signed informed consent Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastroint...
Recifercept is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its pharmacokinetics, safety, and tolerability following single or multiple subcutaneous doses.
Recifercept is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy subjects.
Recifercept is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 24 healthy volunteers. The study was randomized, double-blind, and placebo-controlled, and it took place in Belgium.
Recifercept has one completed Phase 1 clinical trial, identified as NCT04543344. The study evaluated the pharmacokinetic, safety, and tolerability of single or multiple subcutaneous doses of Recifercept in healthy participants aged 21 years and older.
Recifercept is not FDA approved. It is an investigational drug that is still in clinical development. The completed Phase 1 trial focused on healthy volunteers to assess safety and tolerability, and the drug has not yet been studied in patient populations for any specific disease.